|
Title
|
Published
|
Price
|
|
Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
By: BioSeeker Group AB
This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different
|
more...
|
8/25/2009
|
$3,500.00
|
|
Lymphoma Drug Development Strategies at Work - Define Your Competition
By: BioSeeker Group AB
This report includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications
|
more...
|
6/22/2009
|
$2,750.00
|
|
Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
By: BioSeeker Group AB
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an
alternative to small molecule drugs. Alternative binding peptide molecules, derived from
combinatorial scaffold libraries, are now challenging traditional antibodies. This
|
more...
|
5/28/2009
|
$3,400.00
|
|
Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
By: BioSeeker Group AB
This report includes defined and up to date development strategies for 175 leukemia drugs (>250
projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are
further dived into the sub-indications of
|
more...
|
4/3/2009
|
$3,100.00
|
|
Brain Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While
|
more...
|
2/20/2009
|
$2,099.00
|
|
Analytical Tool - Hematological Cancers
By: BioSeeker Group AB
Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a
|
more...
|
1/20/2009
|
$8,330.00
|
|
Analytical Tool - The Commercial Success of Cancer Therapeutic Antibodies
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$5,740.00
|
|
Analytical Tool - Colorectal Cancer
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Colorectal Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal cancer R&D and business development. It is at the same time
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Melanoma
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Melanoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D and business development. It is at the same time a
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Vaccines
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Cancer Vaccines" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine drug development. It is at the same time a
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Angiogenesis in Oncology
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Angiogenesis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Competitive Outlook on Apoptosis in Oncology
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptopic drug development for the treatment of cancer. It is
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Prostate Cancer
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same
|
more...
|
1/20/2009
|
$4,340.00
|
|
Analytical Tool - Protein Kinase Inhibitors in Oncology
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs)
|
more...
|
1/20/2009
|
$4,340.00
|
|
Liver Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
There are today at least 107 therapeutics targeting liver cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years
|
more...
|
1/20/2009
|
$1,399.00
|
|
Pancreatic Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
There are today at least 190 therapeutics targeting pancreatic cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years
|
more...
|
1/20/2009
|
$2,099.00
|
|
Ovarian Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication
|
more...
|
1/20/2009
|
$2,099.00
|
|
Renal Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being
|
more...
|
1/20/2009
|
$2,099.00
|
|
Bladder Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5
|
more...
|
1/20/2009
|
$1,399.00
|
|
Melanoma Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival
|
more...
|
1/20/2009
|
$2,099.00
|
|
Colorectal Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a
|
more...
|
1/20/2009
|
$2,099.00
|
|
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top
|
more...
|
1/20/2009
|
$2,099.00
|
|
Lung Cancer Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of
|
more...
|
1/20/2009
|
$2,099.00
|
|
Lymphoma Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 200 therapeutics targeting lymphoma in active development, from early preclinical to marketed drugs.
|
more...
|
1/20/2009
|
$2,099.00
|
|
Immunotherapy in Oncology: Drug Pipeline Update 2009
By: BioSeeker Group AB
Executive Summary
Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators
|
more...
|
1/20/2009
|
$2,799.00
|
|
Title
|
Published
|
Price
|
(0 items)
